Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
NYSE:STE's Cash-to-Debt is ranked lower than
88% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. NYSE:STE: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:STE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.36 Max: No Debt
Current: 0.2
Equity-to-Asset 0.58
NYSE:STE's Equity-to-Asset is ranked lower than
58% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. NYSE:STE: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:STE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.58 Max: 0.89
Current: 0.58
0.34
0.89
Debt-to-Equity 0.51
NYSE:STE's Debt-to-Equity is ranked lower than
65% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. NYSE:STE: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:STE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.3 Max: 0.76
Current: 0.51
0
0.76
Interest Coverage 5.23
NYSE:STE's Interest Coverage is ranked lower than
84% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. NYSE:STE: 5.23 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:STE' s Interest Coverage Range Over the Past 10 Years
Min: 4.99  Med: 13.64 Max: 20.66
Current: 5.23
4.99
20.66
Piotroski F-Score: 7
Altman Z-Score: 3.18
Beneish M-Score: -2.77
WACC vs ROIC
6.93%
3.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 9.31
NYSE:STE's Operating Margin % is ranked higher than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. NYSE:STE: 9.31 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:STE' s Operating Margin % Range Over the Past 10 Years
Min: 7.06  Med: 12.52 Max: 16.2
Current: 9.31
7.06
16.2
Net Margin % 4.63
NYSE:STE's Net Margin % is ranked higher than
50% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. NYSE:STE: 4.63 )
Ranked among companies with meaningful Net Margin % only.
NYSE:STE' s Net Margin % Range Over the Past 10 Years
Min: 4.21  Med: 7.64 Max: 10.65
Current: 4.63
4.21
10.65
ROE % 4.12
NYSE:STE's ROE % is ranked lower than
56% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. NYSE:STE: 4.12 )
Ranked among companies with meaningful ROE % only.
NYSE:STE' s ROE % Range Over the Past 10 Years
Min: 3.78  Med: 12.93 Max: 18.11
Current: 4.12
3.78
18.11
ROA % 2.36
NYSE:STE's ROA % is ranked lower than
53% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. NYSE:STE: 2.36 )
Ranked among companies with meaningful ROA % only.
NYSE:STE' s ROA % Range Over the Past 10 Years
Min: 2.14  Med: 6.94 Max: 10.46
Current: 2.36
2.14
10.46
ROC (Joel Greenblatt) % 18.16
NYSE:STE's ROC (Joel Greenblatt) % is ranked higher than
58% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. NYSE:STE: 18.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:STE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.35  Med: 29.93 Max: 38.9
Current: 18.16
16.35
38.9
3-Year Revenue Growth Rate 3.80
NYSE:STE's 3-Year Revenue Growth Rate is ranked higher than
50% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. NYSE:STE: 3.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:STE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.8  Med: 7.15 Max: 152.9
Current: 3.8
-19.8
152.9
3-Year EBITDA Growth Rate 0.80
NYSE:STE's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NYSE:STE: 0.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:STE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 6.8 Max: 206.6
Current: 0.8
-18.1
206.6
3-Year EPS without NRI Growth Rate -16.10
NYSE:STE's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. NYSE:STE: -16.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:STE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: 7.75 Max: 293.6
Current: -16.1
-72.2
293.6
GuruFocus has detected 9 Warning Signs with STERIS PLC $NYSE:STE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:STE's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

STE Guru Trades in Q3 2016

Joel Greenblatt 61,525 sh (New)
John Paulson 311,800 sh (New)
Paul Tudor Jones 13,613 sh (+62.06%)
Ken Fisher 1,639,312 sh (+1.04%)
Keeley Asset Management Corp 2,944 sh (+0.03%)
Mario Gabelli 103,000 sh (unchged)
Chuck Royce Sold Out
Jeremy Grantham Sold Out
Jim Simons 297,300 sh (-53.33%)
» More
Q4 2016

STE Guru Trades in Q4 2016

Steven Cohen 207,800 sh (New)
John Paulson 313,500 sh (+0.55%)
Mario Gabelli 103,000 sh (unchged)
Keeley Asset Management Corp Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 1,585,374 sh (-3.29%)
Joel Greenblatt 56,454 sh (-8.24%)
» More
Q1 2017

STE Guru Trades in Q1 2017

Paul Tudor Jones 17,685 sh (New)
John Paulson 423,500 sh (+35.09%)
Mario Gabelli 103,000 sh (unchged)
Steven Cohen Sold Out
Ken Fisher 1,547,816 sh (-2.37%)
Joel Greenblatt 52,911 sh (-6.28%)
» More
Q2 2017

STE Guru Trades in Q2 2017

Steven Cohen 372,300 sh (New)
Joel Greenblatt 172,228 sh (+225.51%)
Mario Gabelli 103,000 sh (unchged)
Ken Fisher 1,493,966 sh (-3.48%)
Paul Tudor Jones 10,961 sh (-38.02%)
John Paulson 131,500 sh (-68.95%)
» More
» Details

Insider Trades

Latest Guru Trades with STE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Reduce -3.48%0.01%$69.22 - $83.11 $ 87.0415%1,493,966
Joel Greenblatt 2017-06-30 Add 225.51%0.14%$69.22 - $83.11 $ 87.0415%172,228
John Paulson 2017-06-30 Reduce -68.95%0.27%$69.22 - $83.11 $ 87.0415%131,500
Ken Fisher 2017-03-31 Reduce -2.37%$66.32 - $72.17 $ 87.0426%1,547,816
John Paulson 2017-03-31 Add 35.09%0.1%$66.32 - $72.17 $ 87.0426%423,500
Joel Greenblatt 2017-03-31 Reduce -6.28%$66.32 - $72.17 $ 87.0426%52,911
Ken Fisher 2016-12-31 Reduce -3.29%0.01%$64.4 - $72.23 $ 87.0428%1,585,374
John Paulson 2016-12-31 Add 0.55%$64.4 - $72.23 $ 87.0428%313,500
Joel Greenblatt 2016-12-31 Reduce -8.24%$64.4 - $72.23 $ 87.0428%56,454
Keeley Asset Management Corp 2016-12-31 Sold Out 0.01%$64.4 - $72.23 $ 87.0428%0
Ken Fisher 2016-09-30 Add 1.04%$67.79 - $73.9 $ 87.0423%1,639,312
John Paulson 2016-09-30 New Buy0.25%$67.79 - $73.9 $ 87.0423%311,800
Joel Greenblatt 2016-09-30 New Buy0.06%$67.79 - $73.9 $ 87.0423%61,525
Keeley Asset Management Corp 2016-09-30 Add 0.03%$67.79 - $73.9 $ 87.0423%2,944
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339113    SIC: 3842
Compare:LSE:AMS, LSE:TSTL, LSE:ODX » details
Traded in other countries:1S4.Germany,
Headquarter Location:UK
STERIS PLC is a provider of infection prevention and other procedural products and services. The Company's business segments are Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies.

STERIS PLC formerly Steris Corp was founded in October 9, 2014. The Company is a provider of infection prevention and other procedural products and services, focused on healthcare, pharmaceutical and research. It offers a mix of capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room ('OR') integration; consumable products, such as detergents and skin care products, gastrointestinal ('GI') endoscopy accessories, and other products; services, including equipment installation and maintenance; and microbial reduction of medical devices, instrument and scope repair solutions, and laboratory testing services. The Company operates in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance and installation services, as well as consumables. Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. Applied Sterilization Technologies segment offers contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The Company is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and in other countries.

Ratios

vs
industry
vs
history
PE Ratio 62.14
STE's PE Ratio is ranked lower than
85% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. STE: 62.14 )
Ranked among companies with meaningful PE Ratio only.
STE' s PE Ratio Range Over the Past 10 Years
Min: 11.08  Med: 22.81 Max: 62.25
Current: 62.14
11.08
62.25
Forward PE Ratio 22.03
STE's Forward PE Ratio is ranked higher than
63% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. STE: 22.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 62.14
STE's PE Ratio without NRI is ranked lower than
85% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. STE: 62.14 )
Ranked among companies with meaningful PE Ratio without NRI only.
STE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.08  Med: 22.87 Max: 62.25
Current: 62.14
11.08
62.25
Price-to-Owner-Earnings 45.56
STE's Price-to-Owner-Earnings is ranked lower than
60% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. STE: 45.56 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
STE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.67  Med: 20.37 Max: 60.59
Current: 45.56
8.67
60.59
PB Ratio 2.49
STE's PB Ratio is ranked higher than
63% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. STE: 2.49 )
Ranked among companies with meaningful PB Ratio only.
STE' s PB Ratio Range Over the Past 10 Years
Min: 1.68  Med: 2.39 Max: 4.19
Current: 2.49
1.68
4.19
PS Ratio 2.89
STE's PS Ratio is ranked higher than
57% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. STE: 2.89 )
Ranked among companies with meaningful PS Ratio only.
STE' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.62 Max: 2.9
Current: 2.89
0.94
2.9
Price-to-Free-Cash-Flow 29.86
STE's Price-to-Free-Cash-Flow is ranked higher than
50% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.92 vs. STE: 29.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
STE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.74  Med: 23.97 Max: 113.68
Current: 29.86
8.74
113.68
Price-to-Operating-Cash-Flow 17.60
STE's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. STE: 17.60 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
STE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.09  Med: 13.96 Max: 25.66
Current: 17.6
7.09
25.66
EV-to-EBIT 35.72
STE's EV-to-EBIT is ranked lower than
79% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. STE: 35.72 )
Ranked among companies with meaningful EV-to-EBIT only.
STE' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.1  Med: 14.7 Max: 40.3
Current: 35.72
7.1
40.3
EV-to-EBITDA 20.54
STE's EV-to-EBITDA is ranked lower than
55% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. STE: 20.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
STE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.4  Med: 10.2 Max: 24.9
Current: 20.54
5.4
24.9
EV-to-Revenue 3.33
STE's EV-to-Revenue is ranked higher than
55% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. STE: 3.33 )
Ranked among companies with meaningful EV-to-Revenue only.
STE' s EV-to-Revenue Range Over the Past 10 Years
Min: 1  Med: 1.7 Max: 3.6
Current: 3.33
1
3.6
Shiller PE Ratio 43.06
STE's Shiller PE Ratio is ranked higher than
61% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. STE: 43.06 )
Ranked among companies with meaningful Shiller PE Ratio only.
STE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.91  Med: 26.75 Max: 43.17
Current: 43.06
17.91
43.17
Current Ratio 2.91
STE's Current Ratio is ranked higher than
50% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. STE: 2.91 )
Ranked among companies with meaningful Current Ratio only.
STE' s Current Ratio Range Over the Past 10 Years
Min: 1.44  Med: 2.45 Max: 8.51
Current: 2.91
1.44
8.51
Quick Ratio 2.30
STE's Quick Ratio is ranked higher than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. STE: 2.30 )
Ranked among companies with meaningful Quick Ratio only.
STE' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.87 Max: 7.97
Current: 2.3
0.92
7.97
Days Inventory 49.50
STE's Days Inventory is ranked higher than
93% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. STE: 49.50 )
Ranked among companies with meaningful Days Inventory only.
STE' s Days Inventory Range Over the Past 10 Years
Min: 44.92  Med: 63.23 Max: 70.76
Current: 49.5
44.92
70.76
Days Sales Outstanding 64.40
STE's Days Sales Outstanding is ranked lower than
64% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. STE: 64.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
STE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.38  Med: 69.06 Max: 82.3
Current: 64.4
62.38
82.3
Days Payable 29.75
STE's Days Payable is ranked lower than
79% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. STE: 29.75 )
Ranked among companies with meaningful Days Payable only.
STE' s Days Payable Range Over the Past 10 Years
Min: 29.75  Med: 34.96 Max: 43.62
Current: 29.75
29.75
43.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.33
STE's Dividend Yield % is ranked higher than
60% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. STE: 1.33 )
Ranked among companies with meaningful Dividend Yield % only.
STE' s Dividend Yield % Range Over the Past 10 Years
Min: 0.6  Med: 1.42 Max: 2.34
Current: 1.33
0.6
2.34
Dividend Payout Ratio 0.80
STE's Dividend Payout Ratio is ranked lower than
85% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. STE: 0.80 )
Ranked among companies with meaningful Dividend Payout Ratio only.
STE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.33 Max: 0.85
Current: 0.8
0.16
0.85
3-Year Dividend Growth Rate 10.00
STE's 3-Year Dividend Growth Rate is ranked higher than
56% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. STE: 10.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
STE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 34.7
Current: 10
0
34.7
Forward Dividend Yield % 1.43
STE's Forward Dividend Yield % is ranked higher than
54% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. STE: 1.43 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.17
STE's 5-Year Yield-on-Cost % is ranked higher than
62% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. STE: 2.17 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
STE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.98  Med: 2.32 Max: 3.82
Current: 2.17
0.98
3.82
3-Year Average Share Buyback Ratio -12.90
STE's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. STE: -12.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
STE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -118.4  Med: -0.45 Max: 5.2
Current: -12.9
-118.4
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.95
STE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
62% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. STE: 1.95 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
STE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.81  Med: 1.61 Max: 58.73
Current: 1.95
0.81
58.73
Price-to-Median-PS-Value 1.79
STE's Price-to-Median-PS-Value is ranked lower than
77% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. STE: 1.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
STE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.99 Max: 3.31
Current: 1.79
0.43
3.31
Earnings Yield (Greenblatt) % 2.84
STE's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. STE: 2.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
STE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 6.8 Max: 14
Current: 2.84
2.5
14
Forward Rate of Return (Yacktman) % 2.52
STE's Forward Rate of Return (Yacktman) % is ranked lower than
71% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. STE: 2.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
STE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 12 Max: 18.7
Current: 2.52
2.5
18.7

More Statistics

Revenue (TTM) (Mil) $2,582.34
EPS (TTM) $ 1.40
Beta1.15
Short Percentage of Float3.56%
52-Week Range $63.80 - 88.11
Shares Outstanding (Mil)85.23

Analyst Estimate

Mar18 Mar19
Revenue (Mil $) 2,570 2,680
EPS ($) 3.94 4.54
EPS without NRI ($) 3.94 4.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.00%
Dividends per Share ($)
» More Articles for STE

Headlines

Articles On GuruFocus.com
UFP Technologies Elects Cynthia Feldmann to its Board Jun 09 2017 
Largest Insider Trades of the Week Sep 09 2016 
Mutual Funds Make Trades in 3 Continents Jul 01 2016 
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
Supply Your Portfolio with Healthy Growth from Medical Suppliers May 25 2012 
STERIS Corp. Reports Operating Results (10-Q) Feb 09 2011 
STERIS Corp. Reports Operating Results (10-Q) Nov 09 2010 
STERIS Corp. (STE) President & CEO Walter M Jr Rosebrough sells 11,600 Shares Oct 01 2010 
STERIS Corp. (STE) SVP & CFO Michael J Tokich sells 9,000 Shares Apr 09 2010 
STERIS Corp. Reports Operating Results (10-Q) Feb 09 2010 

More From Other Websites
STERIS Plc : STE-US: Dividend Analysis : August 29th, 2017 (record date) : By the numbers :... Sep 21 2017
How Much Higher Can Medtech Climb As Investors Flee Pharma? Sep 14 2017
See what the IHS Markit Score report has to say about Steris PLC. Sep 14 2017
Earnings Review and Free Research Report: Steris Reported Strong Results with Growth in Net Income... Aug 29 2017
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions Aug 21 2017
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now Aug 17 2017
Here's Why Investors Should Buy Align Technology (ALGN) Now Aug 16 2017
Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish Aug 16 2017
Varian (VAR) Rides on Oncology and Proton Therapy Businesses Aug 16 2017
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss Aug 15 2017
Featured Company News - Intuitive Surgical Splits Stock in Three for One Ratio Aug 15 2017
Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes Aug 14 2017
STERIS (STE) Banks on Organic Growth, Competition Intense Aug 14 2017
Edited Transcript of STE earnings conference call or presentation 8-Aug-17 2:00pm GMT Aug 13 2017
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife Aug 11 2017
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2 Aug 11 2017
IHS Markit Score downgrades Steris PLC to 64 out of 100, ranking positively in only one out of three... Aug 10 2017
STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up Aug 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}